EDNRA and diabetic kidney disease: 2012). Furthermore, ETAR antagonists are the first‐line treatment option for pulmonary arterial hypertension, and interestingly, are currently being studied for the treatment of diabetic nephropathy (Reichetzeder et al. 2014).